Liquidia's Yutrepia drug approved by court, shares rise 12%, despite patent dispute with United Therapeutics.
Liquidia Corporation's shares rose 12% following a favorable court ruling allowing the launch of its drug Yutrepia, an inhalation powder treating pulmonary hypertension linked to interstitial lung disease. The U.S. district court denied United Therapeutics' request to block the launch due to patent infringement claims, paving the way for the FDA to issue a final decision on the amended drug application.
June 03, 2024
5 Articles